17-DMAP-GA

• UNSPSC Description:

  17-DMAP-GA, a Geldanamycin (HY-15230) analogue, is an inhibitor of HSP90. 17-DMAP-GA causes cell cycle abnormalities[1][2].

• Target Antigen:

  HSP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/17-dmap-ga.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CN(C)CCCNC(C(C=C1NC(/C(C)=C/C=C\[C@@H]2OC)=O)=O)=C(C[C@H](C[C@@H]([C@@H]([C@H](/C=C([C@@H]2OC(N)=O)\C)C)O)OC)C)C1=O

• Molecular Weight:

  630.77

• References & Citations:

  [1]Jurczyszyn A, et al. Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor. J Cancer. 2014;5(6):480-490. Published 2014 May 31.|[2]Tian ZQ, et al. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem. 2004;12(20):5317-5329.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  169521-68-0